The Portnoy Law Firm has announced a class action lawsuit on behalf of Soleno Therapeutics investors who purchased securities between March 6, 2025 and November 4, 2025. The lawsuit alleges that Soleno concealed significant safety risks related to its lead drug DCCR, including excess fluid retention issues discovered in Phase 3 trials. The stock declined 27% on November 4, 2025 following disclosure of commercial disruption and a patient death, with investors having until May 5, 2026 to file a lead plaintiff motion.

A class action lawsuit has been filed against Soleno Therapeutics for allegedly making false statements and concealing safety concerns regarding its DCCR drug candidate for Prader-Willi syndrome treatment. The complaint alleges the company downplayed evidence of fluid retention issues in clinical trials and misrepresented the drug's commercial viability. Investors who purchased shares between March 26, 2025 and November 4, 2025 can apply to be lead plaintiff by May 5, 2026.

A securities class action lawsuit has been filed against Soleno Therapeutics regarding alleged false and misleading statements about safety concerns with its DCCR drug candidate for Prader-Willi syndrome. The lawsuit claims the company downplayed evidence of fluid retention issues in clinical trials and concealed materially greater safety risks, leading to lower commercial viability. Investors who purchased stock between March 26, 2025 and November 4, 2025 may be eligible for compensation, with a lead plaintiff deadline of May 5, 2026.

A class action lawsuit has been filed against Soleno Therapeutics, Inc. alleging that the company failed to disclose significant safety concerns related to its DCCR drug candidate, including excess fluid retention issues in clinical trials. The lawsuit claims these undisclosed risks materially reduced the drug's commercial viability and posed greater safety risks than disclosed to investors who purchased securities between March 26, 2025 and November 4, 2025.

A class action lawsuit has been filed against Atara Biotherapeutics alleging securities fraud. The complaint claims the company made false statements about manufacturing issues and deficiencies in the ALLELE study that would likely prevent FDA approval of tabelecleucel. Investors who purchased Atara securities between May 20, 2024 and January 9, 2026 may be eligible to join the case.

Rosen Law Firm is reminding investors who purchased Soleno Therapeutics common stock between March 26, 2025 and November 4, 2025 of the May 5, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Soleno made false statements regarding safety concerns with its DCCR drug candidate, including undisclosed fluid retention issues in clinical trials, which posed materially greater risks and lower commercial viability than disclosed.

Investor rights law firm Halper Sadeh LLC is investigating four pharmaceutical and real estate companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.

A class action lawsuit has been filed against Soleno Therapeutics for allegedly making false statements about the safety profile of its DCCR drug candidate. The complaint claims the company downplayed safety concerns related to fluid retention in clinical trials for treating Prader-Willi syndrome, resulting in materially greater risks and lower commercial viability than disclosed. Investors who purchased shares between March 26, 2025 and November 4, 2025 can apply to be lead plaintiff by May 5, 2026.

A class action lawsuit has been filed against Soleno Therapeutics, Inc. alleging that the company failed to disclose significant safety concerns related to its DCCR drug candidate, including excess fluid retention issues in clinical trials. The lawsuit claims these undisclosed risks materially reduced the drug's commercial viability and posed greater safety risks than disclosed to investors who purchased securities between March 26, 2025 and November 4, 2025.

Hagens Berman announces a securities class action lawsuit against Soleno Therapeutics (NASDAQ: SLNO) alleging the company concealed safety risks and inflated commercial metrics for its flagship drug VYKAT™ XR for Prader-Willi syndrome treatment. An activist short seller report in August 2025 and Q3 financial results in November 2025 revealed safety concerns and lower-than-expected patient uptake, causing the stock to plunge 27% in a single day. Investors with losses during the March 26 - November 4, 2025 period have until May 5, 2026 to petition as lead plaintiff.

Hagens Berman has filed a securities class action against Soleno Therapeutics (SLNO) alleging the company concealed safety risks and inflated commercial viability metrics for its flagship drug VYKAT™ XR. The complaint claims Soleno downplayed evidence of fluid retention and heart failure risks in children, relied on data from a physician with integrity issues, and artificially inflated launch metrics. Following an activist short seller report in August 2025 and a November 2025 earnings miss revealing lower patient start forms and increased discontinuations, SLNO stock plummeted 27% in a single day. The lead plaintiff deadline is May 5, 2026.

Multiple securities fraud class action lawsuits have been filed against publicly traded companies. Soleno Therapeutics faces allegations of failing to disclose material safety concerns regarding its DCCR drug for Prader-Willi syndrome treatment, including excessive fluid retention risks. Super Micro Computer and ImmunityBio also have pending class action deadlines for investors seeking to recover losses from alleged securities fraud.